Europe Patient Derived Xenograft (PDX) Models Market – Industry Trends and Forecast to 2030

Análisis y tamaño del mercado de modelos de xenoinjerto derivado de pacientes (PDX) en Europa

Según la Sociedad Estadounidense del Cáncer, en 2018 se diagnosticaron 1.735.350 nuevos casos de cáncer en los Estados Unidos. Además, el Instituto Nacional del Cáncer está ampliando su repositorio de modelos de investigación del cáncer en 2018 para incluir más modelos de investigación. Actualmente se están construyendo bibliotecas PDX a gran escala en Europa y los Estados Unidos. El Instituto Nacional del Cáncer de los Estados Unidos anunció planes para realizar la transición de su sistema de detección de fármacos contra el cáncer de la "línea celular tumoral humana NCI-60" a un nuevo sistema. En comparación con los modelos de xenoinjerto derivados de líneas celulares, se espera que los modelos PDX tengan una predictibilidad superior de la eficacia del tratamiento, al tiempo que preservan la heterogeneidad tumoral.

Data Bridge Market Research analiza que el mercado de modelos de xenoinjerto derivado del paciente (PDX), que fue de USD 48002,80 mil en 2022, se espera que alcance los USD 162882,33 mil para 2030, a una CAGR del 16,5% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de modelos de xenoinjerto derivado de pacientes (PDX) en Europa  

Definición de mercado

Los modelos PDX se consideran una herramienta eficaz en la investigación biomédica y los ensayos preclínicos porque ambas especies tienen similitudes y estos modelos son capaces de transmitir las características del tumor y estudiar el tumor y su heterogeneidad. Ayudan a evaluar la tasa de crecimiento del tumor, el ciclo de vida y la tasa de crecimiento en diversas condiciones. También ayudan a distinguir entre el cáncer adulto y pediátrico. El uso de modelos PDX en la investigación básica del cáncer y el desarrollo de alfombras permite la adopción de nuevas terapias, terapias específicas para el paciente y medicina personalizada.

Dinámica del mercado de modelos de xenoinjerto derivado de pacientes (PDX) en Europa

Conductores

• Creciente demanda de modelos PDX para estudios farmacológicos y de biomarcadores

Los modelos singénicos y de xenoinjerto tumoral se han utilizado tradicionalmente para la investigación en farmacología oncológica, biomarcadores y farmacocinética/farmacodinámica. El valor de los modelos PDX en las operaciones normales de investigación ha aumentado a medida que ha aumentado la disponibilidad y el costo de los modelos PDX suministrados tanto por instituciones académicas como por empresas de investigación por contrato. Una revisión superficial de los programas de descubrimiento del cáncer publicados en los últimos tres años revela el uso de modelos PDX en varias etapas del descubrimiento preclínico y la investigación traslacional. Sin embargo, la industria de modelos PDX está incorporando cada vez más la lectura de modelos PDX como un componente crítico del paquete de datos requerido tanto para el uso interno como para la presentación regulatoria. El uso de modelos PDX en el desarrollo de fármacos se remonta a varias décadas.

• La creciente prevalencia de enfermedades crónicas aumenta la demanda de medicamentos personalizados

El desarrollo de medicamentos para enfermedades crónicas como el cáncer ha recibido mucha atención. El cáncer es ahora una carga importante para los sistemas de salud en todo el mundo. Según los datos mundiales sobre el cáncer publicados en 2020, se registraron aproximadamente 18 millones de casos de cáncer y 10 millones de muertes por cáncer en 2020. Se están desarrollando técnicas in vitro e in vivo para abordar la creciente incidencia del cáncer y proporcionar terapias efectivas a los pacientes. El cáncer es una de las principales causas de muerte en todo el mundo. La enfermedad se ha propagado rápidamente y se espera que se propague significativamente durante el período de pronóstico.

Each year, approximately 400 000 children are diagnosed with cancer. The most common cancers differ by country. As a result of the rising global prevalence of cancer, the market is being driven by an increase in the rate of diagnosis and demand for personalized medication.

Opportunities

• Growing adoption of humanized PDX models

Despite the fact that xenografts develop well in immunodeficient models, these models are primarily used to create PDX models. These models are insufficient for investigating stroma-tumour interactions, which are primarily responsible for tumour development and progression in patients. Humanized PDX models help with these challenges and are gaining popularity in the industry. To generate humanized xenograft models, immunodeficient mice (such as NOD SCID mice) are being reconstructed with bone marrow or peripheral blood cells and patient tumour implants. These models are ideal for studying the role of xenogeneic immune cells in overall anti-tumor immunity. They also help with the development of immunotherapy medications that target the immune system's effector arm.

Restraints/Challenges

• Unaffordable personalized PDX models

To develop individualized PDX models, a specimen of the patient's tumour is implanted and grown in a variety of immunocompromised models. It is then extracted, fragmented, and re-implanted in a larger group of models that have been treated with various medications and pharmacological combinations. Given the costs of developing and maintaining these models and the use of expensive medications in these models, PDX trials can cost thousands of dollars, even for a single patient. Using PDX models in government-funded fundamental research, on the other hand, could be prohibitively expensive. These are the primary factors limiting the adoption of PDX models.

This patient derived xenograft (PDX) models market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the patient derived xenograft (PDX) models market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Europe Patient Derived Xenograft (PDX) Models Market

Covid-19 had a negative impact on the Europe patient-derived xenograft (PDX) models market due to the decline in productivity in life science organizations during the pandemic. Reduced pharma R&D deals in therapeutic areas, disruption of clinical trials, and country-specific lockdowns all affected the market. Oncology, ID/anti-infectives, cardiovascular disease, and respiratory disease trials were the most impacted. The market will resume growth as the impact of COVID-19 is expected to weaken in the post-pandemic scenario.

Recent Developments

• In December 2020, Collagen Matrix, Inc., a global leader in collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners ("Linden") announced the acquisition of Sunstar's Degradable Solutions division. It included the GUIDOR branded line of resorbable synthetic medical implants. The acquisition aims to broaden the range of technologies available to customers.
• In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres, and the company signed agreements with Dana-Farber Cancer Institute and the University of Washington. This aids the company's product expansion and provides assistance to the oncology drug development community.

Europe Patient Derived Xenograft (PDX) Models Market Scope

The patient derived xenograft (PDX) models market is segmented on the basis of type, tumour type, application, technique and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Mice Models
• Rat Models

Tumor Type

• Gastrointestinal Tumor Models
• Lung Tumor Models
• Haematological Tumor Models
• Gynecological Tumor Models
• Respiratory Tumor Models
• Urological Tumor Models
• Others

Application

• Preclinical Drug Development
• Precision Medicine
• Co-Clinical Trials
• Basic Cancer Research
• Biomarker Analysis
• Oncology Research

Technique

• Heterotopic Implantation
• Orthotropic Implantation

End User

• Academic and Research Organizations
• Contract Research Organizations
• Pharmaceutical and Biotechnological Companies
• Others

Patient Derived Xenograft (PDX) Models Market Regional Analysis/Insights

The patient derived xenograft (PDX) models market is analyzed and market size insights and trends are provided by country, type, tumour type, application, technique and end user as referenced above.

The countries covered in the patient derived xenograft (PDX) models market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe

Germany is dominating the European market with the growing environmental concerns by environmental agencies on the water quality such as the water framework directive in europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The patient derived xenograft (PDX) models market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for patient derived xenograft (PDX) models market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the patient derived xenograft (PDX) models market. The data is available for historic period 2011-2021.

Competitive Landscape and Patient Derived Xenograft (PDX) Models Market Share Analysis

The patient derived xenograft (PDX) models market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to patient derived xenograft (PDX) models market.

Some of the major players operating in the patient derived xenograft (PDX) models market are:

• Crown Bioscience Inc. (U.S.)
• THE JACKSON LABORATORY (U.S.)
• Champions Oncology, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Wuxi AppTec (China)
• Oncodesign (Canada)
• Aragen Bioscience (India)
• Biocytogen (U.S.)
• Bioduro (U.S.)
• Creative Animodel (U.S.)
• Covance Inc. (U.S.)
• EPO Berlin-Buch GmbH (Germany)
• EUROPDX. (Belgium)
• Explora BioLabs (U.S.)
• Hera BioLabs (U.S.)
• Horizon discovery Ltd. (U.K.)
• Pharmatest Services (Finland)
• Urospehere SAS (Cyprus)
• Xentech (France)
• Xenopat (France)

Research Methodology: Europe Patient Derived Xenograft (PDX) Models Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-23310